We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Saliva Test Rapidly Identifies Paracetamol Overdose

By LabMedica International staff writers
Posted on 06 Dec 2024

Paracetamol is the most widely used medication worldwide, and its easy availability contributes to its frequent misuse and overdose. More...

Overdosing on paracetamol can lead to liver toxicity, requiring hospitalization. Without prompt treatment, it can result in severe consequences such as liver failure, the need for a transplant, or even death. N-acetylcysteine (NAC) is the standard treatment for paracetamol overdose and is effective in preventing acute liver injury (ALI), but it must be administered within 8 hours to be most effective. Quick and accurate paracetamol quantification is critical in guiding overdose treatment. Existing methods typically involve invasive sampling and lengthy processing times. Now, researchers have introduced a groundbreaking technique that allows for rapidly detecting paracetamol levels from saliva.

In a study published in the journal BMC Medicine, a team led by the University of Liverpool (Liverpool, UK) demonstrated the clinical validity of a novel Mass Spectrometry-based technique that tests a small drop of saliva on paper for paracetamol levels. This technique, called Paper-Arrow Mass Spectrometry (PA-MS) was found to offer superior analytical performance with reduced time, resources, and clinical involvement compared to traditional methods.

The research team tested the technique using both saliva and plasma samples from volunteers who had taken paracetamol. They found saliva to be the preferred sample for paracetamol detection. The PA-MS method proved reliable for detecting paracetamol in stimulated saliva, offering a valuable tool for making timely treatment decisions. For the first time, the study also identified differences in paracetamol concentrations between resting and stimulated saliva, underscoring the importance of standardizing saliva collection methods. This breakthrough marks a significant step forward in the development of rapid and convenient saliva-based diagnostic tools.

“This study demonstrates successful testing of the new PA-MS test in a clinical environment and lays the foundation for advancing point-of-care testing across emergency and routine clinical settings,” said Dr. Simon Maher, an expert in Mass Spectrometry Technologies with the University of Liverpool’s Department of Electrical Engineering and Electronics. “This innovation represents a significant step forward in ambient ionization mass spectrometry techniques, with the potential for broad application in clinical diagnostics.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.